Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$63.37−1.32 (-2.04%)
Close on Nov 13, 2026Market cap $9.43BP/E –Yield 0.00%
Vaxcyte operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vaxcyte's operating income for the twelve months ending Sep 30, 2026 was -$1.23B. For fiscal 2025 it was -$923.68M. The highest annual figure on record is -$35.53M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$923.68M | – |
| FY2024 | Dec 31, 2024 | -$569.55M | – |
| FY2023 | Dec 31, 2023 | -$468.04M | – |
| FY2022 | Dec 31, 2022 | -$232.26M | – |
| FY2021 | Dec 31, 2021 | -$103.67M | – |
| FY2020 | Dec 31, 2020 | -$89.58M | – |
| FY2019 | Dec 31, 2019 | -$54.15M | – |
| FY2018 | Dec 31, 2018 | -$35.53M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$308.27M | – |
| Q2 FY2026 | Jun 30, 2026 | -$302.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$345.85M | – |
| Q4 FY2025 | Dec 31, 2025 | -$274.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$242.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$226.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$180.79M | – |
| Q4 FY2024 | Dec 31, 2024 | -$162.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$139.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$152.98M | – |
| Q1 FY2024 | Mar 31, 2024 | -$114.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$196.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$113.03M | – |
| Q2 FY2023 | Jun 30, 2023 | -$87.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$71.19M | – |
| Q4 FY2022 | Dec 31, 2022 | -$86.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$58.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$47.89M | – |
| Q1 FY2022 | Mar 31, 2022 | -$39.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.31M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.60M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.84M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.14M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.23M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.94M | – |
See a number that looks wrong?